Dr. Till is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 855-557-0555Fax+1 206-606-1025
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007- University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2002 - 2005
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2002
Certifications & Licensure
WA State Medical License 2005 - 2025
PA State Medical License 2002 - 2005- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2012 Aug 09
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2018 Mar 06
Roles: Principal Investigator
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Start of enrollment: 2017 Dec 05
Publications & Presentations
PubMed
- 18 citationsCombination of Cytokine-Induced Killer Cells and Programmed Cell Death-1 Blockade Works Synergistically to Enhance Therapeutic Efficacy in Metastatic Renal Cell Carcin...Zibing Wang, Xiaoli Liu, Brian G. Till, Miaomiao Sun, Xiang Li
Frontiers in Immunology. 2018-07-05 - 17 citationsMulticentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.Marcus Geer, Emily Roberts, Maryann Shango, Brian G. Till, Stephen D. Smith
British Journal of Haematology. 2019-07-01 - 19 citationsEligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCLStephen D. Smith, Prathima Reddy, Alexandra O. Sokolova, Victor A. Chow, Ryan C. Lynch
American Journal of Hematology. 2019-04-01
Abstracts/Posters
- Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell LymphomasBrian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...Brian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical OutcomesBrian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
- Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
